April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Bromfenac Ophthalmic Solution in Dry Eye: Ocular Surface Disease Index subscale response
Author Affiliations & Notes
  • Simon P. Chandler
    ISTA Pharmaceuticals, Inc., Irvine, California
  • Sheri L. Rowen
    Mercy Medical Center, Baltimore, Maryland
  • Neal A. Sher
    Eye Care Associates, Minneapolis, Minnesota
  • Timothy R. McNamara
    ISTA Pharmaceuticals, Inc., Irvine, California
  • James A. Gow
    ISTA Pharmaceuticals, Inc., Irvine, California
  • Sebrin Siraj
    University of Southern California, School of Pharmacy, Irvine, California
  • Footnotes
    Commercial Relationships  Simon P. Chandler, ISTA Pharmaceuticals, Inc. (E, R, I); Sheri L. Rowen, ISTA Pharmaceuticals, Inc. (C, R); Neal A. Sher, ISTA Pharmaceuticals, Inc. (C, R); Timothy R. McNamara, ISTA Pharmaceuticals, Inc. (I, E, R); James A. Gow, ISTA Pharmaceuticals, Inc. (I, E, R); Sebrin Siraj, ISTA Pharmaceuticals, Inc. (C, R)
  • Footnotes
    Support  ISTA Pharmaceuticals, Inc.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3832. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simon P. Chandler, Sheri L. Rowen, Neal A. Sher, Timothy R. McNamara, James A. Gow, Sebrin Siraj; Bromfenac Ophthalmic Solution in Dry Eye: Ocular Surface Disease Index subscale response. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3832.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the Ocular Surface Disease Index (OSDI) subscale responses of subjects with dry eye disease using RemuraTM (bromfenac ophthalmic solution) over a six week period.

Methods: : This is a retrospective analysis of 38 subjects diagnosed with dry eye disease who were dosed with Remura BID for 42 days in an open label, Phase 2, clinical trial. The OSDI responses were re-analyzed at the level of the subscales for symptoms, visual function, and environmental triggers. Scores for each subscale were produced as means of the summed sub scale question scores and plotted versus visit day. Changes in subscale score compared to baseline were performed and analyzed using a paired t-test. The subject-reported worst factor in each subscale was defined and the change from baseline calculated.

Results: : Subjects dosing with Remura showed a reduction in each of the subscales; the change from baseline at each study visit for each of the subscales was statistically significant. The change from baseline in subscale score was significant as early as 14 days versus baseline. The worst factors reported for each subscale are those commonly associated with moderate dry eye.

Conclusions: : Remura treats the common symptoms associated with mild-moderate dry eye disease with efficacy evident within 14 days of treatment.

Clinical Trial: : http://www.clinicaltrials.gov NCT00758784

Keywords: cornea: tears/tear film/dry eye • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.